Welcome to Reader Training Renal

Reader Training is an educational resource provided by Telix Pharmaceuticals,Inc. 

To access the Reader Training modules you must be a registered user of TelixU and logged in.

Following guidance from experienced PET/CT readers, this reader training program is designed to optimize PET/CT reading skills for 89Zr-girentuximab and increase confidence in identifying renal pathology. These learning modules include, anatomy review, tracer and technical considerations, video case studies with teaching points and interactive Test Your Knowledge opportunities.

Target Audience: NM physicians, radiologists, urologists, radiation oncologists, oncologists, surgeons, & referring physicians.

Sort by: Title | Newest
* Module 1: Introduction | 89Zr-girentuximab Reader Training
A conversation with: Jeremie Calais, MD, MSc
13850

Dr. Jeremie Calais, MD, PhD provides foundational knowledge about the application of 89Zirconium-girentuximab PET/CT scan including patient selection and management such as prep, positioning, and post scan discharging protocols.  Based upon his experience, fine-tuning the technical considerations supporting the PET/CT imaging protocols, camera settings, as well as understanding the isotope presentation, is critical to delivering a successful 89Zirconium-girentuximab PET/CT program.

Keeping the overall goal of improving care for patients presenting with renal carcinoma, a comprehensive PET/CT report is needed and should include specific details for the care team members.

Teaching Points

  • Improve one’s foundational knowledge of the technical and patient considerations of 89Zirconium-girentuximab PET/CT scanning
  • Review the renal anatomy and expected 89Zirconium-girentuximab effects on renal pathology.
  • Confidently deliver results utilizing 89Zirconium-girentuximab for the diagnosis and management of renal carcinoma.
  • Prepare a comprehensive 89Zirconium-girentuximab PET/CT report.

Note: “Test Your Knowledge” competency measurements in the form of quiz questions, will be displayed throughout the module. Upon completion of this Module, a post-test will be offered to provide a Statement of Participation.

Meet the Faculty

Jeremie Calais MD PhD Jeremie Calais, MD, PhD
Associate Professor, Department of Molecular and Medical Pharmacology
Director, Theranostics Program
Ahmanson Translational Theranostics Division
David Geffen School of Medicine at UCLA

Dr Jeremie Calais, MD, PhD, is a nuclear medicine physician specialized in cancer imaging and theranostics working at the University of California Los Angeles (UCLA) since 2016. He serves as the Director of the Theranostics and Clinical Research Programs of the Ahmanson Translational Theranostics Division and as an Associate Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). He is a Certified Principal Investigator (CPI) by The Association of Clinical Research Professionals (ACRP) and conducts academic investigator-initiated and industry sponsored trials using targeted radionuclide imaging and therapy.

* Module 2: Renal PET/CT | 89Zr-girentuximab Reader Training
A conversation with: Viraj Master, MD, PhD, FACS | Brian M. Shuch, MD
13852

This reader training module provides the referring physician’s perspective toward the clinical impact and advantages of 89Zirconium-girentuximab PET/CT in renal cancer diagnosis, management, and care.

Dr. Master and Dr. Shuch discuss the importance of understanding the epidemiology, commonality, and types of renal cancer. Through case study examples, oncologic challenges and improved outcomes will be presented. The overall goal is to provide the basis needed to develop and deliver a comprehensive PET/CT report that guides the care team members.

Teaching Points

  • Confidently recognize renal pathology associated with renal cell carcinoma.
  • Understand the clinical benefits of 89Zirconium-girentuximab PET/CT imaging.
  • Identify the renal anatomy and expected 89Zirconium-girentuximab effects on renal pathology.
  • Prepare and deliver a comprehensive 89Zirconium-girentuximab PET/CT report.

Note: “Test Your Knowledge” competency measurements in the form of quiz questions, will be displayed throughout the module. Upon completion of this Module, a post-test will be offered to provide a Statement of Participation.

Meet the Faculty

Viraj Master, MD, PhD, FACS (Photo)Viraj Master, MD, PhD, FACS
Professor, Director of Urological Research
Emory University Medical Center

Dr. Master’s primary clinical interest is urologic oncology, in particular kidney cancer, adrenal tumors, testicular cancer, high-risk prostate cancer and penile cancers. Dr. Master is a renowned national expert in the surgical treatment of kidney cancer particularly a complex variety that extends into the main blood vessels and the heart. He also has a special interest in minimally invasive laparoscopic technique that removes of cancerous lymph nodes with minimal interference with the patients’ quality of life.

As the Director of Clinical Research, he is active in investigating the role of inflammation in cancers and in researching “host” (patient) interaction with the disease. In his role as Associate Chair for Clinical Affairs and Quality, he works closely with all faculty members towards a common goal of providing the highest quality of care to patients. He serves as an expert advisor to the American Cancer Society on prostate cancer and to the International Consultation on Urologic Diseases on kidney cancer. He has lectured both nationally and internationally. He is closely involved in teaching and mentoring medical students, urology residents and post-graduate fellows. He has authored multiple book chapters and scientific journal articles.

Brian M. Shuch, MD (Photo)Brian M. Shuch, MD
Director of the Kidney Cancer Program
UCLA Health

Dr. Shuch completed medical school at NYU, a six-year urology residency at UCLA, and a three-year Urologic Oncology Fellowship at the National Cancer Institute. He is an accomplished surgeon and clinical/translational researcher. He serves in leadership positions including the NCI Renal Task Force, SWOG, the Kidney Cancer Association, and the Society of Urologic Oncology. He is recognized as an expert in kidney cancer genetic syndromes and runs a translational research program with ~200 peer reviewed publications in prestigious journals such as Nature, Nature Genetics, NEJM, Lancet, Lancet Oncology, PNAS, JCO, and CCR. He has received funding from the NCI/NIH, DOD, KureIt, KCA, V Foundation, Driven to Cure, and the Phase One Foundation and previously Dr. Shuch was at Yale from 2013-2018 as an Associate Professor of Urology..

In addition to being the acting Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research. Dr. Shuch directs UCLA's Multidisciplinary VHL Program and the Society of Urologic Oncology Fellowship Program.

* Module 3: Advanced Reading Skills | 89Zr-girentuximab Reader Training
A conversation with: Jeremie Calais, MD, MSc | James Nagarajah, MD | Sze Ting Lee, MD, PhD
13854

This module is designed to assist the reader in advancing their 89Zirconium-girentuximab PET/CT interpretation skills in order to prepare a comprehensive report detailing findings supporting patients with renal carcinoma and advancing pathology. perspective toward the clinical impact of 89Zirconium-girentuximab PET/CT in ccRCC diagnosis, management, and care.

Through case reviews, three (3) expert faculty share examples of how to navigate and interpret negative cases, initial staging cases, challenging and complex cases; with the goal of providing clear direction for patient management following the 89Zirconium-girentuximab PET/CT scanning.

By viewing Modules 1, 2 and 3 of the 89Zirconium-girentuximab PET/CT reader training program, the reader should be prepared to assume the role of consultant to the referring physician(s) when 89Zirconium-girentuximab PET/CT scanning is introduced into the patient’s journey.

Teaching Points

  • Review case study examples that demonstrate the clinical utility of 89Zirconium-girentuximab PET/CT scan and improve reader confidence.
  • Establish a methodical approach to reviewing image findings of 89Zirconium-girentuximab PET/CT scans.
  • Increase the 89Zirconium-girentuximab PET/CT reader’s skills through a comprehensive case study review.
  • Develop a concise 89Zirconium-girentuximab PET/CT scan report.

Note: “Test Your Knowledge” competency measurements in the form of quiz questions, will be displayed throughout the module. Upon completion of Parts 1, 2, and 3 of this Module, a post-test will be offered to provide a Statement of Participation.

Meet the Faculty

Jeremie Calais MD PhDPart 1
Jeremie Calais, MD, PhD
Associate Professor, Department of Molecular and Medical Pharmacology
Director, Theranostics Program
Ahmanson Translational Theranostics Division
David Geffen School of Medicine at UCLA

Dr Jeremie Calais, MD, PhD, is a nuclear medicine physician specialized in cancer imaging and theranostics working at the University of California Los Angeles (UCLA) since 2016. He serves as the Director of the Theranostics and Clinical Research Programs of the Ahmanson Translational Theranostics Division and as an Associate Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). He is a Certified Principal Investigator (CPI) by The Association of Clinical Research Professionals (ACRP) and conducts academic investigator-initiated and industry sponsored trials using targeted radionuclide imaging and therapy.

James Nagarajah, MD (Photo)Part 2
James Nagarajah, MD
Assistant Professor,
Dept of Radiology and Nuclear Medicine
Radboud University Medical Centre

 

Bio needed.

Sze Ting Lee, MD, PhD (Photo)Part 3
Sze Ting Lee, MD, PhD
Professor, Deputy Director & Nuclear Medicine Physician
Austin Health
Melbourne, Australia

Professor Lee is a Nuclear Medicine Physician at Austin Health in Melbourne, with extensive nuclear medicine expertise and is very highly regarded in the nuclear medicine community. She holds a Bachelor of Medicine / Bachelor of Surgery from Monash University and is also a fellow of the Royal Australasian College of Physicians, the Australasian Association of Nuclear Medicine Specialists and the Asian Nuclear Medicine Board. Her current positions include Deputy Medical Director and Director of Training, Department of Molecular Imaging & Therapy at Austin Health; Professor, School of Health and Biomedical Sciences, RMIT University; Associate Professor, Department of Medicine and Department of Surgery at the University of Melbourne; Associate Professor, School of Cancer Medicine, La Trobe University; and Senior Clinical Research Fellow at the Olivia Newton-John Cancer Research Institute.

Professor Lee is also a Council Member, Adult Medicine Division, Royal Australasian College of Physicians; Scientific Advisory Panel of the Australia and New Zealand Society of Nuclear Medicine; Committee Member and OTP Assessor, Committee for Joint College Training, and Training Site Accreditation Committee; and Deputy Chair, International Relations Committee, Australia and New Zealand Society of Nuclear Medicine (ANZSNM). She is the Immediate Past President of the Australasian Association of Nuclear Medicine Specialists (AANMS); Past President of the ANZSNM, and previous Secretary-General of the World Federation of Nuclear Medicine and Biology.